Fondazione Italiana Linfomi - ETS
Milan, MI
What changed
Study registered, no phase assigned: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.
6mo agoTrial registeredJan 5, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 49 out of 100, unchanged since the last recompute.
Some recent activity, at a steady rate.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Grant-only
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Peer position
8,719 pre-ticker oncology companies at Grant-only
Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.
Compare seatsA ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
Study registered
Feb 8, 2023Mantle Cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Fondazione Italiana Linfomi - ETS · Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.
ClinicalTrials.gov · NCT04882475 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources